P/E ratio for OPKO Health (OPK)
P/E ratio as of April 2024 (TTM): -4.67
According to OPKO Health 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.66667. At the end of 2022 the company had a P/E ratio of -2.84.
P/E ratio history for OPKO Health from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.84 | -97.05% |
| 2021 | -96.2 | -221.77% |
| 2020 | 79.0 | -2948.3% |
| 2019 | -2.77 | -75.12% |
| 2018 | -11.1 | 20.58% |
| 2017 | -9.25 | -96.02% |
| 2016 | -233 | 101.42% |
| 2015 | -115 | 362.19% |
| 2014 | -25.0 | -5.31% |
| 2013 | -26.4 | -39.68% |
| 2012 | -43.7 | |
| 2010 | -45.9 | 301.09% |
| 2009 | -11.4 | 48.26% |
| 2008 | -7.71 | 928.57% |
| 2007 | -0.7500 | -96.19% |
| 2006 | -19.7 | 44.15% |
| 2005 | -13.7 | 382.35% |
| 2004 | -2.83 | 19.63% |
| 2003 | -2.37 | 346.62% |
| 2002 | -0.5303 | -90.92% |
| 2001 | -5.84 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -322.31% | 🇺🇸 USA |
 Abbott Laboratories ABT | 36.2 | -875.11% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 23.7 | -606.81% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -342.27% | 🇺🇸 USA |
 LabCorp LH | 26.4 | -665.21% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -34.9 | 648.46% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -6.91 | 47.96% | 🇮🇱 Israel |
 Ardelyx ARDX | -53.6 | 1,048.21% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.